Besides emricasan, an in vivo study by Morrison et al. showed that treatment with Ac-YVAD-cmk, another casp1 inhibitor, blocked NASH development and insulin resistance in male LDLR−/−.Leiden mice (70). This evidence concerns the gene CASP1 and metabolic dysfunction-associated steatohepatitis.